Lyra Therapeutics, Inc. (LYRA) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Lyra Therapeutics, Inc. (LYRA) Bundle
Designed for accuracy, our (LYRA) DCF Calculator enables you to evaluate Lyra Therapeutics, Inc. valuation using up-to-date financial data and complete flexibility to modify all key parameters for enhanced projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .3 | 1.4 | 1.6 | 2.0 | 2.6 | 3.3 | 4.3 | 5.5 |
| Revenue Growth, % | 0 | 0 | 0 | 378.25 | 14.31 | 28.58 | 28.58 | 28.58 | 28.58 | 28.58 |
| EBITDA | -16.5 | -22.1 | -42.6 | -53.9 | -65.3 | -.4 | -.5 | -.7 | -.9 | -1.1 |
| EBITDA, % | 100 | 100 | -14952.28 | -3956.2 | -4188.06 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .0 | .1 | 1.0 | 1.1 | .3 | 1.6 | 2.0 | 2.6 | 3.4 | 4.3 |
| Depreciation, % | 100 | 100 | 351.23 | 78.28 | 17.84 | 79.23 | 79.23 | 79.23 | 79.23 | 79.23 |
| EBIT | -16.5 | -22.2 | -43.6 | -55.0 | -65.5 | -.4 | -.5 | -.7 | -.9 | -1.1 |
| EBIT, % | 100 | 100 | -15303.51 | -4034.48 | -4205.91 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 9.8 | 74.6 | 45.7 | 97.9 | 102.8 | 2.0 | 2.6 | 3.3 | 4.3 | 5.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .8 | 1.0 | 1.3 | 1.7 | 2.2 |
| Account Receivables, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .8 | 1.0 | 1.3 | 1.7 | 2.2 |
| Inventories, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 1.1 | .9 | 3.1 | 2.6 | 3.1 | 2.0 | 2.6 | 3.3 | 4.3 | 5.5 |
| Accounts Payable, % | 100 | 100 | 1096.49 | 191.93 | 200.96 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.2 | -1.8 | -3.4 | -.2 | -1.0 | -.7 | -.9 | -1.2 | -1.5 | -2.0 |
| Capital Expenditure, % | 100 | 100 | -1187.72 | -12.03 | -67.2 | -35.85 | -35.85 | -35.85 | -35.85 | -35.85 |
| Tax Rate, % | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 | -0.09421759 |
| EBITAT | -16.3 | -22.1 | -42.5 | -55.0 | -65.6 | -.4 | -.5 | -.7 | -.8 | -1.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.4 | -24.0 | -42.7 | -54.6 | -65.8 | -2.3 | .7 | .9 | 1.2 | 1.5 |
| WACC, % | 4.65 | 4.68 | 4.61 | 4.7 | 4.7 | 4.67 | 4.67 | 4.67 | 4.67 | 4.67 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 2 | |||||||||
| Terminal Value | 59 | |||||||||
| Present Terminal Value | 47 | |||||||||
| Enterprise Value | 48 | |||||||||
| Net Debt | 5 | |||||||||
| Equity Value | 44 | |||||||||
| Diluted Shares Outstanding, MM | 50 | |||||||||
| Equity Value Per Share | 0.88 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real LYRA financials.
- Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe the effect of your inputs on Lyra Therapeutics’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive Financial Data: Gain access to precise pre-loaded historical figures and future forecasts for Lyra Therapeutics, Inc. (LYRA).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic recalculations for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries for a clear view of your valuation outcomes.
- Suitable for All Skill Levels: Designed with an intuitive layout for investors, CFOs, and consultants alike.
How It Works
- 1. Download the Model: Obtain and open the Excel template containing Lyra Therapeutics, Inc.'s (LYRA) financial data.
- 2. Adjust Key Variables: Modify essential inputs such as revenue growth, discount rate, and capital investments.
- 3. Analyze Results in Real-Time: The DCF model automatically computes the intrinsic value and net present value.
- 4. Explore Different Scenarios: Evaluate various projections to understand potential valuation impacts.
- 5. Present with Assurance: Deliver expert valuation analysis to inform your strategic choices.
Why Choose This Calculator?
- Comprehensive Tool: Features DCF, WACC, and financial ratio analyses tailored for Lyra Therapeutics, Inc. (LYRA).
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Lyra Therapeutics' intrinsic value and Net Present Value.
- Preloaded Data: Utilizes historical and projected data for precise calculations.
- Professional Quality: Perfect for financial analysts, investors, and consultants focusing on Lyra Therapeutics, Inc. (LYRA).
Who Should Use This Product?
- Pharmaceutical Students: Understand drug development processes and apply theoretical knowledge using real-world examples.
- Researchers: Integrate advanced therapeutic models into studies or academic projects.
- Healthcare Investors: Evaluate your investment strategies and analyze market potential for Lyra Therapeutics, Inc. (LYRA).
- Market Analysts: Enhance your analysis with a customizable model tailored for biotech evaluations.
- Healthcare Entrepreneurs: Discover how innovative companies like Lyra Therapeutics, Inc. (LYRA) are positioned within the industry.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Lyra Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Lyra Therapeutics, Inc. (LYRA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.